Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Recruiting 8Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Urinary Bladder Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1HER2-positive Gastric Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × disitamab vedotin × Clear all
NCT07366840 2026-01-26

BRIGHT

Fudan University

Phase 2/3 Not yet recruiting
268 enrolled
Breast

Breast Neoplasms

NCT06015113 2023-08-29

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Xi'an International Medical Center Hospital

Phase NA Not yet recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡